Myeloma Current Events | Myeloma News | 2
|
|
|
Sort By:
Page Views | Date |
Mayo Clinic Cancer Center — individualizing treatment for multiple myeloma patients
Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of... view more... (2006-12-11)
Investigating the measles virus as a tool to kill multiple myeloma
Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill cancer. view more (2007-03-06)
A chemotherapy drug packs a one-two punch
Cancer can be wily, and those who treat the disease have amassed a wide array of weapons with which to fight it and kill tumors. view more (2007-02-21)
ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
Results from two investigational Phase I trials of ZOLINZA® (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. view more (2007-12-10)
Penn's Abramson Cancer Center part of major phase III study for myeloma
Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow. view more (2007-11-26)
Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream
A team of researchers from the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) have developed an optical device that allows them to peer through the eyes of a mouse and monitor the cells passing through its bloodstream. view more (2007-12-04)
Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation. view more (2005-09-09)
REVLIMID improves overall survival and delays disease progression in multiple myeloma patients
Celgene Corporation (NASDAQ: CELG) announced updated clinical data from two Phase III pivotal studies evaluating REVLIMID (lenalidomide) plus dexamethasone in previously treated multiple myeloma patients. view more (2005-12-13)
Individuals who apply pesticides are found to have double the risk of blood disorder
A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general... view more... (2009-06-15)
Novel drug preventing protein recycling shows potential for treating leukemia
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins. view more (2007-04-20)
Mayo Clinic: New recommendations for use of bisphosphonates in treatment of multiple myeloma
Mayo Clinic's multiple myeloma (MM) research team has jointly issued a consensus statement regarding the use of bisphosphonates to prevent or treat bone disease in MM. view more (2006-08-11)
Mayo Clinic Proceedings: Common blood disorder may not be linked to as many serious diseases
A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. view more (2009-08-26)
Studies attribute recent increase in multiple myeloma survival to novel therapies
Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade. view more (2007-11-02)
Slight risk of leukaemia among UK nuclear test veterans "cannot be ruled out"
Nuclear test veterans are not at increased risk of premature death and developing cancer, overall, finds research in Occupational and Environmental Medicine. But the possibility that they may have a slightly increased risk of leukaemia, "cannot be ruled out," the authors conclude. The researchers from the UK's National Radiological... view more... (2003-02-21)
Rapid restoration of immunity in immune-suppressed cancer patients using T-cell vaccines
Patients with multiple myeloma suffer from a malignant proliferation of plasma cells in their bone marrow. view more (2005-10-21)
VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients
The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma. view more (2008-09-03)
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. view more (2008-10-07)
Experimental procedure induces tolerance to mismatched kidney transplants
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs. view more (2008-01-24)
USC study finds that green tea blocks benefits of cancer drug
Contrary to popular assumptions about the health benefits of green tea, researchers at the University of Southern California (USC) have found that the widely used supplement renders a cancer drug used to treat multiple myeloma and mantle cell lymphoma completely ineffective in treating cancer. view more (2009-02-04)
Getting down to cancer basics
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes. The new example - a gene on the X chromosome called UTX - is found in 10% of cases of multiple myeloma and 8% of esophageal cancers. view more (2009-03-30)
|
|
|
|
Sort By:
Page Views | Date |
|
